id.DRIVE (former COVIDRIVE)

id.DRIVE is a privately funded not-for-profit public-private partnership (PPP) that facilitates the conduct of infectious diseases studies on vaccines, related preventive measures, therapeutics and diagnostics in the European region. The id.DRIVE consortium is open to new partners (public health institutes, pharmaceutical companies, small-medium enterprises, academia…) and new study sites (Study Contributors).

id.DRIVE was launched in 2024 as the successor of COVIDRIVE, a PPP that was set-up during the COVID-19 pandemic to address the joint need to monitor COVID-19 vaccination programmes for public health institutes in Europe and to assess brand-specific COVID-19 vaccine effectiveness for the pharmaceutical companies as part of their regulatory obligations. COVIDRIVE leveraged an existing vaccine effectiveness platform (DRIVE) which provided yearly brand-specific influenza vaccine effectiveness estimates to EMA.

id.DRIVE expands the scope of COVIDRIVE beyond COVID-19 and will study many different infectious diseases.